NASDAQ:BNTC Benitec Biopharma 5/13/2024 Earnings Report $14.98 -0.61 (-3.88%) As of 03:22 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Benitec Biopharma EPS ResultsActual EPS-$1.64Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ABenitec Biopharma Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ABenitec Biopharma Announcement DetailsQuarterDate5/13/2024TimeN/AConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Benitec Biopharma Earnings HeadlinesHC Wainwright Has Optimistic Outlook of BNTC FY2025 EarningsMay 23, 2025 | americanbankingnews.comBenitec Biopharma (NASDAQ:BNTC) Earns Buy Rating from HC WainwrightMay 21, 2025 | americanbankingnews.comThe Social Security Changes No One’s Talking AboutWhile most Americans worry about their next Social Security check... something far bigger is happening behind the scenes. An AI plan — authorized by Executive Order — is about to rewrite how the SSA operates.May 30, 2025 | Altimetry (Ad)Equities Analysts Offer Predictions for BNTC FY2025 EarningsMay 20, 2025 | americanbankingnews.comBenitec Biopharma: An Under-The-Radar And Undervalued Gene Therapy DeveloperApril 16, 2025 | seekingalpha.comBenitec Biopharma price target raised to $20 from $18 at Citizens JMPApril 12, 2025 | markets.businessinsider.comSee More Benitec Biopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Benitec Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Benitec Biopharma and other key companies, straight to your email. Email Address About Benitec BiopharmaBenitec Biopharma (NASDAQ:BNTC), a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.View Benitec Biopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles e.l.f. Beauty Sees Record Surge After Earnings, Rhode DealCrowdStrike Stock Slips: Analyst Downgrades Before Earnings Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsAdvance Auto Parts: Did Earnings Defuse Tariff Concerns?Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH StockAdvance Auto Parts Jumps on Surprise Earnings BeatAlibaba's Earnings Just Changed Everything for the Stock Upcoming Earnings CrowdStrike (6/3/2025)Haleon (6/4/2025)Broadcom (6/5/2025)Oracle (6/10/2025)Adobe (6/12/2025)Accenture (6/20/2025)FedEx (6/24/2025)Micron Technology (6/25/2025)Paychex (6/25/2025)NIKE (6/26/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
